H

Hua Medicine
HKEX:2552

Watchlist Manager
Hua Medicine
HKEX:2552
Watchlist
Price: 1.3 HKD -2.26% Market Closed
Market Cap: 1.3B HKD

Hua Medicine
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hua Medicine
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
H
Hua Medicine
HKEX:2552
Cost of Revenue
-ÂĄ67.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cost of Revenue
-ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cost of Revenue
-ÂĄ6.1B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cost of Revenue
-ÂĄ3.9B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cost of Revenue
-ÂĄ28.8B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cost of Revenue
-ÂĄ242.3m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Hua Medicine
Glance View

Market Cap
1.3B HKD
Industry
Pharmaceuticals

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.

Intrinsic Value
0.37 HKD
Overvaluation 72%
Intrinsic Value
Price
H

See Also

What is Hua Medicine's Cost of Revenue?
Cost of Revenue
-67.9m CNY

Based on the financial report for Jun 30, 2024, Hua Medicine's Cost of Revenue amounts to -67.9m CNY.

What is Hua Medicine's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-87%

Over the last year, the Cost of Revenue growth was -87%.

Back to Top